Abstract
High-dose benzodiazepine (BZD) abuse is emerging as a substance use disorder (SUD). The aim of the study is to explore the impact of high-dose lormetazepam (LMZ) abuse and the characteristics of patients affected by this SUD in a tertiary referral addiction unit. We have retrospectively evaluated 1112 patients admitted to the Addiction Medicine Unit, Verona University Hospital, Italy for detoxification from high-dose BZD dependence. LMZ was the most common BZD, with an increasing prevalence from January 2003 to June 2018. Socio-demographic (more women; higher age and education) and clinical features (higher daily diazepam dosage equivalent, BZD abuse duration, age of first BZD intake; BZD prescribed more frequently for sleep disorders; less frequent history of other SUDs, previous/active alcohol, previous opioids abuse; more frequent overall major psychiatric diseases and major depression; less-frequent bipolar disorders and other psychoses, personality disorders, and more than one psychiatric disease) of LMZ vs. other BZD abusers significantly differed. 96.7% LMZ abusers took oral solution, while two-thirds of other BZD abusers took tablets. Oral solution, BZD abuse duration and prescription of BZD for sleep disorders increased, while history of other SUDs, previous/active alcohol and active cannabinoids SUD reduced the risk of high-dose LMZ vs. other BZDs abuse. The large prevalence of high-dose LMZ abusers in Italy may be strongly related to the availability and characteristics of oral formulation that may transform the innocuous Dr. Jekyll tablets into an evil Mr. Hyde. Restriction to the market of LMZ oral formulation might reduce the risk of high-dose abuse.
Similar content being viewed by others
References
Lader M (2011) Benzodiazepines revisited-will we ever learn? Addiction 106:2086–2109
Janhsen K, Roser P, Hoffmann K (2015) The problems of long-term treatment with benzodiazepines and related substances. Prescribing practice, epidemiology and the treatment of withdrawal. Dtsch Arztebl Int 112:1–7
Soyka M (2017) Treatment of benzodiazepine dependence. N Engl J Med 376:1147–1157
Kurko TA, Saastamoinen LK, Tähkäpää S, Tuulio-Henriksson A, Taiminen T, Tiihonen J, Airaksinen MS, Hietala J (2015) Long-term use of benzodiazepines: definitions, prevalence and usage patterns—a systematic review of register-based studies. Eur Psychiatry 30:1037–1047
Faccini M, Leone R, Opri S, Casari R, Resentera C, Morbioli L, Conforti A, Lugoboni F (2016) Slow subcutaneous infusion of flumazenil for the treatment of long-term, high-dose benzodiazepine users: a review of 214 cases. J Psychopharmacol 30:1047–1053
Liebrenz M, Schneider M, Buadze A, Gehring MT, Dube A, Caflisch C (2015) High-dose benzodiazepine dependence: a qualitative study of patients' perceptions on initiation, reasons for use, and obtainment. PLoS ONE 10:e0142057
Lugoboni F, Mirijello A, Faccini M, Casari R, Cossari A, Musi G, Bissoli G, Quaglio G, Addolorato G (2014) Quality of life in a cohort of high-dose benzodiazepine dependent patients. Drug Alcohol Depend 142:105–109
Tamburin S, Federico A, Faccini M, Casari R, Morbioli L, Sartore V, Mirijello A, Addolorato G, Lugoboni F (2017) Determinants of quality of life in high-dose benzodiazepine misusers. Int J Environ Res Public Health 14:38
Federico A, Tamburin S, Maier A, Faccini M, Casari R, Morbioli L, Lugoboni F (2017) Multifocal cognitive dysfunction in high-dose benzodiazepine users: a cross-sectional study. Neurol Sci 38:137–142
Petitjean S, Ladewig D, Meier CR, Amrein R, Wiesbeck GA (2007) Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. Int Clin Psychopharmacol 22:292–298
Cosci F, Guidi J, Balon R, Fava GA (2015) Clinical methodology matters in epidemiology: not all benzodiazepines are the same. Psychother Psychosom 84:262–264
Cloos JM, Bocquet V, Rolland-Portal I, Koch P, Chouinard G (2015) Hypnotics and triazolobenzodiazepines—best predictors of high-dose benzodiazepine use: results from the Luxembourg National Health Insurance Registry. Psychother Psychosom 84:273–283
Ozawa M, Nakada Y, Sugimachi K, Akai T, Yamaguchi M (1991) Interaction of the hypnotic lormetazepam with central benzodiazepine receptor subtypes omega 1, omega 2 and omega 3. Nihon Yakurigaku Zasshi 98:399–408
Kaufmann WA, Humpel C, Alheid GF, Marksteiner J (2003) Compartmentation of alpha 1 and alpha 2 GABA(A) receptor subunits within rat extended amygdala: implications for benzodiazepine action. Brain Res 964:91–99
Zecca L, Reina L, Scaglione F, Ferrario P, Pirola R, Ceccarelli G, Ciampini M, Fraschini F (1985) Relative bioavailability in humans for oral tablets and solutions of lormetazepam. Arzneimittelforschung 35:1870–1872
Guerra P, Soto A, Carcas AJ, Sancho A, Cassinello A, Frias-Iniesta J (2002) Comparison of lormetazepam solution and capsules in healthy volunteers. early exposure and drug pharmacokinetics. Clin Drug Invest 22:859–866
Ancolio C, Tardieu S, Soubrouillard C, Alquier C, Pradel V, Micallef J, Blin O (2004) A randomized clinical trial comparing doses and efficacy of lormetazepam tablets or oral solution for insomnia in a general practice setting. Hum Psychopharmacol 19:129–134
Faccini M, Leone R, Pajusco B, Quaglio G, Casari R, Albiero A, Donati M, Lugoboni F (2012) Lormetazepam addiction: data analysis from an Italian medical unit for addiction. Risk Manag Healthc Policy 5:43–48
Tamburin S, Faccini M, Casari R, Federico A, Morbioli L, Franchini E, Bongiovanni LG, Lugoboni F (2017) Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence. J Psychopharmacol 31:1369–1373
American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Press, Washington (text revision)
Galanter M, Kleber HD (2008) The American psychiatric publishing textbook of substance abuse treatment, 4th edn. American Psychiatric Publishers, Arlington
First MB, Spitzer RL, Gibbon M, Williams JBW (2002) Structured clinical interview for DSM-IV-TR Axis I disorders, patient edition (SCID-I/P). Biometrics Research, New York State Psychiatric Institute, New York
Zanarini M, Frankenburg F, Sickel A, Yong L (1996) The diagnostic interview for DSM-IV personality disorders (DIPD-IV). McLean Hospital, Belmont
Hosmer DW, Lemeshow S (2000) Applied logistic regression, 2nd edn. Wiley, New York
Hermos JA, Young MM, Lawler EV, Rosenbloom D, Fiore LD (2007) Long-term, high-dose benzodiazepine prescriptions in veteran patients with PTSD: influence of preexisting alcoholism and drug-abuse diagnoses. J Trauma Stress 20:909–914
Agenzia Italiana del Farmaco (AIFA) (2018) The Medicines Utilisation Monitoring Centre. National Report on Medicines use in Italy. Year 2017. Rome: Italian Medicines Agency. https://www.aifa.gov.it/content/luso-dei-farmaci-italia-rapporto-osmed-2017. Accessed 3 Feb 2019.
Vicente-Sánchez MP, Macías-Saint-Gerons D, de la Fuente-Honrubia C, González-Bermejo D, Montero-Corominas D, Catalá-López F (2013) Trends of use of anxiolytics and hypnotics in Spain from 2000 to 2011. Rev Esp Salud Publica 87:247–255
Baldwin DS, Aitchison K, Bateson A, Curran HV, Davies S, Leonard B, Nutt DJ, Stephens DN, Wilson S (2013) Benzodiazepines: risks and benefits: a reconsideration. J Psychopharmacol 27:967–971
Hoffmann F (2013) Benefits and risks of benzodiazepines and Z-drugs: comparison of perceptions of GPs and community pharmacists in Germany. Ger Med Sci 2013(11):10
Eudra Vigilance Database (2018) https://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000679.jsp. Accessed 30 Sep 2018
Tan KR, Brown M, Labouèbe G, Yvon C, Creton C, Fritschy JM, Rudolph U, Lüscher C (2010) Neural bases for addictive properties of benzodiazepines. Nature 463:769–774
Tan KR, Rudolph U, Luscher C (2011) Hooked on benzodiazepines: GABAA receptor subtypes and addiction. Trends Neurosci 34:188–197
Cheng T, Wallace DM, Ponteri B, Tuli M (2018) Valium without dependence? Individual GABAA receptor subtype contribution toward benzodiazepine addiction, tolerance, and therapeutic effects. Neuropsychiatr Dis Treat 14:1351–1361
Calixto E (2016) GABA withdrawal syndrome: GABAA receptor, synapse, neurobiological implications and analogies with other abstinences. Neuroscience 313:57–72
Fang SY, Chen CY, Chang IS, Wu EC, Chang CM, Lin KM (2009) Predictors of the incidence and discontinuation of long-term use of benzodiazepines: a population-based study. Drug Alcohol Depend 104:140–146
Italian Ministry of Health (2017) Alcohol: guide to use. Rome: Italian Ministry of Health. https://www.salute.gov.it/portale/salute/p1_5.jsp?lingua=italiano&id=81&area=Vivi_sano. Accessed 27 Sep 2018
Cosci F, Mansueto G, Faccini M, Casari R, Lugoboni F (2016) Socio-demographic and clinical characteristics of benzodiazepine long-term users: Results from a tertiary care center. Compr Psychiatry 69:211–215
Magrini N, Vaccheri A, Parma E, D'Alessandro R, Bottoni A, Occhionero M, Montanaro N (1996) Use of benzodiazepines in the Italian general population: prevalence, pattern of use and risk factors for use. Clin Pharmacol 50:19–25
Olfson M, King M, Schoenbaum M (2015) Benzodiazepine use in the United States. JAMA Psychiatry 72:136–142
Van Der Waals FW, Mohrs J, Foets M (1993) Sex differences among recipients of benzodiazepines in Dutch general practice. BMJ 307:363–366
Pélissolo A, Notides C, Lépine JP, Bisserbe JC (1999) Anxiolytic and hypnotic use by general hospital inpatients: the impact of psychopathology and general medical conditions. Gen Hosp Psychiatry 21:79–86
Kazim M, Abar A, Hanif M, Mansoor S, Tahir S, Mehmood A, Yousafzai AW (2015) Pattern of benzodiazepine prescription in internal medicine outpatients at a tertiary care hospital in Pakistan. Postgrad Med Inst 29:38–42
Donoghue J, Lader M (2010) Usage of benzodiazepines: a review. Psychiatry Clin Pract 14:78–87
Tamburin S, Federico A, Morbioli L, Faccini M, Casari R, Zamboni L, Briguglio G, Lugoboni F (2017) Screening for adult attention deficit/hyperactivity disorder in high-dose benzodiazepine dependent patients. Am J Addict 26:610–614
O'Brien PL, Karnell LH, Gokhale M, Kenneth Pack BS, Campopiano M, Zur J (2017) Prescribing of benzodiazepines and opioids to individuals with substance use disorders. Drug Alcohol Depend 178:223–230
Bramness JG, Skurtveit S, Furu K, Engeland A, Sakshaug S, Rønning M (2006) Changes in sale and use of flunitrazepam in Norway after 1999. Tidsskr Nor Laegeforen 126:589–590
Mounteney J, Haugland S (2009) Earlier warning: a multi-indicator approach to monitoring trends in the illicit use of medicines. Int J Drug Policy 20:161–169
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there is no conflict of interest.
Statement of human and animal rights
The study was conducted according to the Declaration of Helsinki and approved by the ethics committee of the Verona University Hospital.
Informed consent
All the patients gave written informed consent to the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Faccini, M., Tamburin, S., Casari, R. et al. High-dose lormetazepam dependence: strange case of Dr. Jekyll and Mr. Hyde. Intern Emerg Med 14, 1271–1278 (2019). https://doi.org/10.1007/s11739-019-02101-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-019-02101-8